Skip to content

POELMAN

Active Private limited companyfounded 1985active for 40 yearsStaatsbaan 128D, 3945 Tessenderlo-HamKBO/BCE: BE 0428.334.479 subsidiary of

Lifetime

20 annual accounts with figures on one time axis, 40 filings since 1986
peak of €224,783 in 2023
€179,864▼ 18.5%
lowest -€20,391 in 2012
€29,776▼ 55.5%
peak of €269,976 in 2011
€65,390▲ 0.8%
€644,551▲ 16.4%
peak of 2.7 FTE in 2014
2.1 FTE▼ 19.2%
Board4 names since 2012
2 directors and 1 other
Owners
99.2%
Documentsfilings and deeds
08-06-202653 days before the deadline
2025abbreviated format
Gross margin from €220,676 to €179,864Result from €66,986 to €29,776Staff from 2.6 FTE to 2.1 FTEDividend €29,250Debts from €553,872 to €644,551

Key points

from the 2025 annual accounts

Equity

€65,390 from €269,976 in 2011

Equity fell by 76% in 14 years.

Turnover

≈ €840,000 estimated

The abbreviated format states no turnover.

Debts

€644,551 91% of the balance sheet
Financial debts 22%Suppliers 50%Taxes and wages 2%Other 27%

Of this, €504,530 falls due within a year.

Staff

4 employees on 31-12-2025
222021202022302023122024432025

In 2025, 4 employees joined and 3 left.

Filings

40 annual accounts since 1986
AprilJune31 JulyOctober1990200020102020

Two of the last ten came late. The 2024 accounts came in latest, 28 days after the end of the period.

Position in the sector

9.2%

Lower solvency than 81% of companies in retail trade. Sector median 36.9% · 13,267 companies.

Checked score

Bankruptcy probability within 12 months

Financial strength

Score breakdown

Comparable companies, two years later

In July 2024, 1,083 companies had the same profile as POELMAN has now. Each dot stands for 3 companies, two years later.

96.9%
were still trading
2.2%
stopped another way
0.8%
went bankrupt
  • Micro
  • 20 years or older
  • solvency under 10%
  • a profit under 5% of the balance sheet
Test of the method

The method was tested on the 497,965 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 2.9% 3.1%
10 5.6% 6.1%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 1,083 companies, not a prediction for POELMAN. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Board and ownership

Manager, since 09-02-2012
Director, since 09-02-2012
  • 99.2%equity €1.6m (2025) · annual accounts 2025 of
Board & ownership

Recent changes

Registered in the Peppol Directory Reachable for e-invoices through 0208:0428334479
changes role from manager to director acts as permanent representative · “De exploitatie,huur en verhuur van één of meer apotheken; Het verzorgen van vervangingen van en voor één of…” (deed in Dutch) · 750 shares · General meeting of 09-03-2023 · Gazette deed
New manager appointed, resigned · acts as permanent representative · Director discharge: (manager) · General meeting of 09-02-2012 · Gazette deed
First establishment Staatsbaan 128D, Tessenderlo-Ham
All 51 events

Comparable companies

same main activity, similar in size and age
Company
POELMAN Tessenderlo-Ham €709,941 €179,864 9.2% 2.1
MEER APOTHEEK Hoogstraten €705,802 €168,352 46.4% 1.8
APOTHEEK KAREL LANGEN Bilzen-Hoeselt €610,859 €202,303 39.0% 1.9
Apoteek G. en J. Bijnens Genk €674,078 €236,300 48.0% 1.8
APOTHEEK BOITS Heusden-Zolder €705,427 €185,283 2.8% 1.6
APOTHEEK ROGGEN ZAVENTEM Zaventem €643,203 €173,276 48.4% 1.8
PHARMACIE LEMMENS Baelen €747,725 €207,434 12.3% 1.8

These companies have the same main activity as POELMAN: retail sale of pharmaceutical products (NACE 47730). They are comparable in size and age: total assets between €611,000 and €748,000, founded between 1986 and 1992.

Official details

Source: KBO
Status
Active since 27-12-1985Normal situation
Activity
Retail sale of pharmaceutical productsNACE 47730
Joint committee
313Pharmacies and pricing offices · annual accounts 2025
Establishment unit
2.028.562.7803945 Tessenderlo-Ham, since 01-01-1986
Financial year end
31 December
Peppol
Reachable since 18-09-2025
Company details

Annual accounts 2025

€709,941▲ 14.7%
Employeeson 31-12-2025
4=
Filing
Filed on 08-06-2026, 53 days before the end of the filing period
Financials

Insights on POELMAN

POELMAN files the abbreviated format. That format states no turnover. The gross margin rose from €145,421 in 2006 to €179,864 in 2025.

holds 99.2% of the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.

Key facts about POELMAN

What is the company number of POELMAN?
The company number of POELMAN is 0428.334.479. The VAT number is the same number with BE in front: BE 0428.334.479.
Where is POELMAN based?
The registered office is at Staatsbaan 128D, 3945 Tessenderlo-Ham.Company details
What does POELMAN do?
According to the KBO register, the main activity is retail sale of pharmaceutical products (NACE 47730).
What is the legal form of POELMAN?
POELMAN is a private limited company (BV).
When was POELMAN founded?
POELMAN was founded on 27-12-1985.
Is POELMAN still active?
Yes, POELMAN is an active enterprise in the KBO register.
How many employees does POELMAN have?
POELMAN had an average of 2.1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
Which joint committee does POELMAN fall under?
In its 2025 annual accounts, POELMAN states joint committee 313 (Pharmacies and pricing offices).
What is the turnover of POELMAN?
The turnover in financial year 2025 is ≈ €840,000. This figure is estimated from the gross margin of €179,864 and 43 comparable companies (NACE 477). It probably lies between €550,000 and €1.8m.
Is POELMAN profitable?
In financial year 2025, POELMAN made a profit of €29,776.
Where can I find the annual accounts of POELMAN?
POELMAN filed 40 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of POELMAN due?
POELMAN must file the annual accounts for financial year 2026 by 31-07-2027.Timeline

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.